Novartis, Bayer Settle IP Spat Over Hemophilia Drugs
The vaccines division of Swiss drugmaker Novartis AG has reached a settlement and licensing deal with Bayer HealthCare LLC in a patent infringement suit over Bayer hemophilia drugs Kogenate and Helixate....To view the full article, register now.
Already a subscriber? Click here to view full article